3 Stocks Pushing The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 108 points (0.7%) at 16,372 as of Friday, March 28, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,438 issues advancing vs. 544 declining with 153 unchanged.

The Health Care sector currently sits up 0.1% versus the S&P 500, which is up 0.8%. On the negative front, top decliners within the sector include Gilead ( GILD), down 3.1%, and Biogen Idec ( BIIB), down 1.3%. Top gainers within the sector include Smith & Nephew ( SNN), up 2.4%, WellPoint ( WLP), up 2.4%, Intuitive Surgical ( ISRG), up 2.2%, HCA Holdings ( HCA), up 2.2% and Valeant Pharmaceuticals International ( VRX), up 2.1%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Biomarin Pharmaceutical is down $1.80 (-2.6%) to $67.11 on average volume. Thus far, 737,882 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $66.68-$69.69 after having opened the day at $69.38 as compared to the previous trading day's close of $68.91.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $10.1 billion and is part of the drugs industry. Shares are down 2.0% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Biomarin Pharmaceutical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half